Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patients

Lung Cancer

Volumn 81, Issue 3, 2013, Pages 468-474

  Heuvers, Marlies E ^a   Muskens, Femke ^a   Bezemer, Koen ^a   Lambers, Margaretha ^a   Dingemans, Anne Marie C ^b   Groen, Harry J M ^c   Smit, Egbert F ^d   Hoogsteden, Henk C ^a   Hegmans, Joost P J J ^a   Aerts, Joachim G J V ^a,e  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e AMPHIA HOSPITAL   (Netherlands)

Author keywords

Arginase 1; Immuno oncology; Myeloid derived suppressor cells; NSCLC

Indexed keywords

ARGINASE 1; MESSENGER RNA;

ADULT; ARTICLE; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CRYOPRESERVATION; FEMALE; FLOW CYTOMETRY; HUMAN; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPPRESSOR CELL;

ARGINASE-1; IMMUNO-ONCOLOGY; MYELOID-DERIVED SUPPRESSOR CELLS; NSCLC;

AGED; ARGINASE; CARCINOMA, NON-SMALL-CELL LUNG; CRYOPRESERVATION; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; LEUKOCYTES, MONONUCLEAR; LUNG NEOPLASMS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MYELOID CELLS; NEOPLASM STAGING; PHENOTYPE; RNA, MESSENGER; T-LYMPHOCYTE SUBSETS;

EID: 84881662613     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.06.005     Document Type: Article

References (33)

1. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30:1073-1081.
2. Tang S., Lotze M.T. The power of negative thinking: which cells limit tumor immunity??. Clin Cancer Res 2012.
3. Poschke I., Kiessling R. On the armament and appearances of human myeloid-derived suppressor cells. Clin Immunol 2012, 144:250-268.
4. Dilek N., Vuillefroy de Silly R., Blancho G., Vanhove B. Myeloid-derived suppressor cells: mechanisms of action and recent advances in their role in transplant tolerance. Front Immunol 2012, 3:208.
5. Filipazzi P., Huber V., Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother 2012, 61:255-263.
6. Sinha P., Parker K.H., Horn L., Ostrand-Rosenberg S. Tumor-induced myeloid-derived suppressor cell function is independent of IFNgamma and IL-4Ralpha. Eur J Immunol 2012.
7. Filipazzi P., et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007, 25:2546-2553.
8. Feng P.H., et al. CD14+S100A9+ Monocytic Myeloid-Derived Suppressor Cells and Their Clinical Relevance in Non-Small Cell Lung Cancer. Am J Respir Crit Care Med 2012.
9. Youn J.I., Gabrilovich D.I. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 2010, 40:2969-2975.
10. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012, 12:253-268.
11. Buijs N., Luttikhold J., Houdijk A.P., van Leeuwen P.A. The role of a disturbed arginine/no metabolism in the onset of cancer cachexia: a working hypothesis. Curr Med Chem 2012.
12. Hoechst B., et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 2009, 50:799-807.
13. Lechner M.G., Liebertz D.J., Epstein A.L. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 2010, 185:2273-2284.
14. Lyons A.B. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods 2000, 243:147-154.
15. Brandau S., et al. Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J Leukoc Biol 2011, 89:311-317.
16. Rodriguez P.C., et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009, 69:1553-1560.
17. Choi J., et al. CD15+/CD16low human granulocytes from terminal cancer patients: granulocytic myeloid-derived suppressor cells that have suppressive function. Tumour Biol 2012, 33:121-129.
18. Kotsakis A., et al. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J Immunol Methods 2012, 381:14-22.
19. Srivastava M.K., et al. Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol Immunother 2008, 57:1493-1504.
20. Liu C.Y., et al. Population alterations of l-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14(-)/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol 2010, 136:35-45.
21. Suzuki K., et al. Prognostic immune markers in non-small cell lung cancer. Clin Cancer Res 2011, 17:5247-5256.
22. Srivastava M.K., et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One 2012, 7:e40677.
23. Kuss I., et al. Recent thymic emigrants and subsets of naive and memory T cells in the circulation of patients with head and neck cancer. Clin Immunol 2005, 116:27-36.
24. Zea A.H., et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005, 65:3044-3048.
25. Rodriguez P.C., Ochoa A.C. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 2008, 222:180-191.
26. Popovic P.J., Zeh H.J., Ochoa J.B. Arginine and immunity. J Nutr 2007, 137:1681S-1686S.
27. Zhang C., et al. Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension 2004, 44:935-943.
28. Lee J., Ryu H., Ferrante R.J., Morris S.M., Ratan R.R. Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox. Proc Natl Acad Sci U S A 2003, 100:4843-4848.
29. Rodriguez P.C., Quiceno D.G., Ochoa A.C. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 2007, 109:1568-1573.
30. Jadus M.R., et al. Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention. Clin Dev Immunol 2012, 2012:160724.
31. Zitvogel L., et al. Integration of host-related signatures with cancer cell-derived predictors for the optimal management of anticancer chemotherapy. Cancer Res 2010, 70:9538-9543.
32. Rodriguez P.C., et al. L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol 2003, 171:1232-1239.
33. Rodriguez P.C., et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004, 64:5839-5849.